1. Home
  2. DFDV vs VRCA Comparison

DFDV vs VRCA Comparison

Compare DFDV & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DFDV

DeFi Development Corp.

HOLD

Current Price

$4.68

Market Cap

132.1M

Sector

Finance

ML Signal

HOLD

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$7.54

Market Cap

137.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DFDV
VRCA
Founded
2018
2013
Country
United States
United States
Employees
16
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.1M
137.3M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
DFDV
VRCA
Price
$4.68
$7.54
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$45.00
$17.00
AVG Volume (30 Days)
782.7K
89.5K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$35,577,000.00
Revenue This Year
$32.58
N/A
Revenue Next Year
$23.65
$94.44
P/E Ratio
$0.90
N/A
Revenue Growth
N/A
370.22
52 Week Low
$2.96
$0.49
52 Week High
$53.88
$9.82

Technical Indicators

Market Signals
Indicator
DFDV
VRCA
Relative Strength Index (RSI) 55.43 58.94
Support Level $3.11 $7.24
Resistance Level $5.16 $7.51
Average True Range (ATR) 0.36 0.66
MACD 0.03 0.04
Stochastic Oscillator 63.52 57.45

Price Performance

Historical Comparison
DFDV
VRCA

About DFDV DeFi Development Corp.

DeFi Development Corp is a U.S. company committed to building its treasury around Solana (SOL), a fast-growing blockchain infrastructure platform. This equity delivers shareholders tangible exposure to SOL price movement and staking rewards, making the firm a proxy for the Solana ecosystem. The treasury extends to running its own validator infrastructure, allowing DFDV to actively participate in and benefit from the Solana network expansion. The firm has two segments: Digital Asset Treasury ("Treasury") and Real Estate Platform ("Real Estate"). The company generates the majority of its revenue from the Treasury segment.

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

Share on Social Networks: